Voya Investment Management LLC Sells 14,585 Shares of Moderna, Inc. $MRNA

Key Points

• Voya Investment Management LLC has cut its stake in Moderna, Inc. by 9.7%, holding 135,307 shares worth approximately $3.84 million after selling 14,585 shares in the first quarter.
• Moderna reported a quarterly revenue of $142 million, exceeding analyst estimates, but still demonstrated a 41.1% year-over-year decline in revenue.
• Research analysts have mixed opinions on Moderna, with a consensus rating of "Hold" and a price target averaging $41.81.

Voya Investment Management LLC lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 9.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 135,307 shares of the company's stock after selling 14,585 shares during the period. Voya Investment Management LLC's holdings in Moderna were worth $3,836,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in Moderna by 1.8% in the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock valued at $54,382,000 after acquiring an additional 34,034 shares during the last quarter. Wealthfront Advisers LLC boosted its stake in shares of Moderna by 143.3% during the 1st quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company's stock worth $879,000 after acquiring an additional 18,268 shares during the period. Jump Financial LLC boosted its stake in Moderna by 5,590.0% in the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company's stock valued at $25,584,000 after purchasing an additional 886,567 shares during the period. FORA Capital LLC lifted its position in shares of Moderna by 31.7% during the 1st quarter. FORA Capital LLC now owns 97,072 shares of the company's stock valued at $2,752,000 after acquiring an additional 23,344 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock worth $74,557,000 after purchasing an additional 285,662 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on MRNA shares. Morgan Stanley reissued an "equal weight" rating and issued a $32.00 target price on shares of Moderna in a research report on Friday, August 1st. Cowen began coverage on Moderna in a report on Sunday, July 13th. They issued a "hold" rating on the stock. Evercore ISI set a $32.00 price objective on shares of Moderna in a research note on Friday, August 1st. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a report on Friday, August 1st. Finally, Citigroup assumed coverage on shares of Moderna in a report on Friday, August 1st. They issued a "neutral" rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $41.81.

Moderna Trading Up 6.0%

MRNA stock traded up $1.52 during mid-day trading on Monday, hitting $26.76. 10,781,504 shares of the company were exchanged, compared to its average volume of 10,947,848. The firm has a fifty day simple moving average of $27.57 and a 200 day simple moving average of $27.90. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $67.96. The company has a market capitalization of $10.41 billion, a PE ratio of -3.56 and a beta of 1.93.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same period in the previous year, the firm posted ($3.33) earnings per share. The firm's revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.